J&J suing Samsung Bioepis over Stelara biosimilar

J&J sues Samsung Bioepis over Stelara biosimilar
Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis treatment.
J&J Takes Samsung Bioepis to Court Over ‘Unlawful’ Stelara Biosimilar Sublicense
Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private label of a Stelara biosimilar.
Biosimilar Battle: J&J Sues Samsung Over Stelara Market Intrusion
Johnson & Johnson filed a lawsuit against Samsung Bioepis for allegedly breaching their agreement over the launch of Stelara's biosimilar, Pyzchiva. J&J seeks to prevent its U.S. sales, claiming unauthorized sublicense dealing damaged J&J's market share.
Samsung Bioepis Announces US Launch of PYZCHIVA® (ustekinumab-ttwe), Biosimilar to Stelara
Samsung Bioepis Co., Ltd. today announced that PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been approved for the treatment of moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy,
J&J sues Samsung Bioepis over ‘surreptitious’ breach of Stelara biosimilar contract
Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous settlement.
J&J sues Samsung Bioepis over contract breach for Stelara biosimilar
Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the drugmaker over the launch of a biosimilar to Stelara, J&J's autoimmune drug.
J&J sues Samsung over a contract breach for a Stelara biosimilar
As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one manufacturer of striking a
Pharmabiz1d
Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients
Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients: Basel Tuesday, February 25, 2025, 14:00 Hrs [IST] Sandoz, the global leader in ge ...
조선일보2d
Samsung recruits foreign R&D talent to boost global competitiveness in Korea
Samsung is securing foreign talent to enhance its global competitiveness.
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars ...
AFP3d
Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™)
Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCE™ (60mg pre-filled syringe) and XBRYK™ (120mg vial), denosumab biosimilars ...